Fidia Farmaceutici buys controlling stake in Meditrina Pharmaceuticals

Business Forum
Italian pharmaceutical company Fidia Farmaceutici, specializing in regenerative medicine and the use of hyaluronic acid in advanced therapeutic applications, has purchased a majority stake in Meditrina Pharmaceuticals.

Meditrina Pharmaceuticals is a Romanian pharmaceutical distributor active in therapeutic areas such as dermatology, gynecology, urology, and nephrology. 

“This is a strategic transaction and reflects investors' confidence in the potential of the local pharmaceutical sector,” says Liliana Busoiu, Partner at EY Parthenon Financial Diligence Leader, Romania.

EY Romania has provided financial and tax advisory services to Fidia Farmaceutici.

RECOMMENDED
RECOMMENDED FROM THE HOME PAGE
IMF cuts growth forecast for Romania
Economy

IMF cuts growth forecast for Romania

The IMF projects that Romania's economy will grow by 1% in 2025 and 1.4% in 2026, according to a report released at the end of a mission in the country.

READ MORE
Business Forum  |  12 September, 2025 at 6:47 PM
Business Forum  |  12 September, 2025 at 6:11 PM